Johnson & Johnson JNJ shares,
rose 0.9% in Monday’s negotiations as the company approaches the early release of provisional results from a final-stage clinical trial evaluating its single-dose candidate vaccine COVID-19. J&J said in mid-December that it expects to share the results of the Phase 3 trial by the end of January, which would be the third company testing coronavirus vaccines in the U.S. to announce the results of a closely watched Phase 3 trial. The other two vaccines, developed by BioNTech SE BNTX,
/ Pfizer Inc. PFE,
and Moderna Inc. MRNA,
both are mRNA-based vaccines that received emergency use authorization from the Food and Drug Administration in December. J&J said in December that it will apply for emergency authorization for its experimental adenovirus-based vaccine in February, if the results are ready by the end of January. The company is due to release its fourth quarter and full-year earnings on Tuesday. J&J shares were up 10.9% last year, while the S&P 500 SPX,
increased by 15.6%.
